Skip to main content
. 2022 Jun 2;10(6):1303. doi: 10.3390/biomedicines10061303

Figure 3.

Figure 3

Hidradenitis suppurativa clinical response at weeks 12 to 16. The meta-analysis illustrated adalimumab (risk ratio 1.77, 95% confidence interval 1.50–2.09, I2 = 26%, 5 randomized controlled trials) and bimekizumab (risk ratio 2.25, 95% confidence interval 1.03–4.92, 1 randomized controlled trial) are the only two effective biologics in treating moderate-to-severe hidradenitis suppurativa.